Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model

Background Recent clinical trials have demonstrated the possible pleiotropic effects of SGLT2 (sodium-glucose cotransporter 2) inhibitors in clinical cardiovascular diseases. Atrial electrical and structural remodeling is important as an atrial fibrillation (AF) substrate. Methods and Results The pr...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American Heart Association Vol. 10; no. 2; p. e017483
Main Authors Nishinarita, Ryo, Niwano, Shinichi, Niwano, Hiroe, Nakamura, Hironori, Saito, Daiki, Sato, Tetsuro, Matsuura, Gen, Arakawa, Yuki, Kobayashi, Shuhei, Shirakawa, Yuki, Horiguchi, Ai, Ishizue, Naruya, Igarashi, Tazuru, Yoshizawa, Tomoharu, Oikawa, Jun, Hara, Yoshinobu, Katsumura, Takafumi, Kishihara, Jun, Satoh, Akira, Fukaya, Hidehira, Sakagami, Hiroyuki, Ako, Junya
Format Journal Article
LanguageEnglish
Published England John Wiley and Sons Inc 19.01.2021
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background Recent clinical trials have demonstrated the possible pleiotropic effects of SGLT2 (sodium-glucose cotransporter 2) inhibitors in clinical cardiovascular diseases. Atrial electrical and structural remodeling is important as an atrial fibrillation (AF) substrate. Methods and Results The present study assessed the effect of canagliflozin (CAN), an SGLT2 inhibitor, on atrial remodeling in a canine AF model. The study included 12 beagle dogs, with 10 receiving continuous rapid atrial pacing and 2 acting as the nonpacing group. The 10 dogs that received continuous rapid atrial pacing for 3 weeks were subdivided as follows: pacing control group (n=5) and pacing+CAN (3 mg/kg per day) group (n=5). The atrial effective refractory period, conduction velocity, and AF inducibility were evaluated weekly through atrial epicardial wires. After the protocol, atrial tissues were sampled for histological examination. The degree of reactive oxygen species expression was evaluated by dihydroethidium staining. The atrial effective refractory period reduction was smaller ( =0.06) and the degree of conduction velocity decrease was smaller in the pacing+CAN group compared with the pacing control group ( =0.009). The AF inducibility gradually increased in the pacing control group, but such an increase was suppressed in the pacing+CAN group ( =0.011). The pacing control group exhibited interstitial fibrosis and enhanced oxidative stress, which were suppressed in the pacing+CAN group. Conclusions CAN and possibly other SGLT2 inhibitors might be useful for preventing AF and suppressing the promotion of atrial remodeling as an AF substrate.
AbstractList Background Recent clinical trials have demonstrated the possible pleiotropic effects of SGLT2 (sodium-glucose cotransporter 2) inhibitors in clinical cardiovascular diseases. Atrial electrical and structural remodeling is important as an atrial fibrillation (AF) substrate. Methods and Results The present study assessed the effect of canagliflozin (CAN), an SGLT2 inhibitor, on atrial remodeling in a canine AF model. The study included 12 beagle dogs, with 10 receiving continuous rapid atrial pacing and 2 acting as the nonpacing group. The 10 dogs that received continuous rapid atrial pacing for 3 weeks were subdivided as follows: pacing control group (n=5) and pacing+CAN (3 mg/kg per day) group (n=5). The atrial effective refractory period, conduction velocity, and AF inducibility were evaluated weekly through atrial epicardial wires. After the protocol, atrial tissues were sampled for histological examination. The degree of reactive oxygen species expression was evaluated by dihydroethidium staining. The atrial effective refractory period reduction was smaller (P=0.06) and the degree of conduction velocity decrease was smaller in the pacing+CAN group compared with the pacing control group (P=0.009). The AF inducibility gradually increased in the pacing control group, but such an increase was suppressed in the pacing+CAN group (P=0.011). The pacing control group exhibited interstitial fibrosis and enhanced oxidative stress, which were suppressed in the pacing+CAN group. Conclusions CAN and possibly other SGLT2 inhibitors might be useful for preventing AF and suppressing the promotion of atrial remodeling as an AF substrate.Background Recent clinical trials have demonstrated the possible pleiotropic effects of SGLT2 (sodium-glucose cotransporter 2) inhibitors in clinical cardiovascular diseases. Atrial electrical and structural remodeling is important as an atrial fibrillation (AF) substrate. Methods and Results The present study assessed the effect of canagliflozin (CAN), an SGLT2 inhibitor, on atrial remodeling in a canine AF model. The study included 12 beagle dogs, with 10 receiving continuous rapid atrial pacing and 2 acting as the nonpacing group. The 10 dogs that received continuous rapid atrial pacing for 3 weeks were subdivided as follows: pacing control group (n=5) and pacing+CAN (3 mg/kg per day) group (n=5). The atrial effective refractory period, conduction velocity, and AF inducibility were evaluated weekly through atrial epicardial wires. After the protocol, atrial tissues were sampled for histological examination. The degree of reactive oxygen species expression was evaluated by dihydroethidium staining. The atrial effective refractory period reduction was smaller (P=0.06) and the degree of conduction velocity decrease was smaller in the pacing+CAN group compared with the pacing control group (P=0.009). The AF inducibility gradually increased in the pacing control group, but such an increase was suppressed in the pacing+CAN group (P=0.011). The pacing control group exhibited interstitial fibrosis and enhanced oxidative stress, which were suppressed in the pacing+CAN group. Conclusions CAN and possibly other SGLT2 inhibitors might be useful for preventing AF and suppressing the promotion of atrial remodeling as an AF substrate.
Background Recent clinical trials have demonstrated the possible pleiotropic effects of SGLT2 (sodium–glucose cotransporter 2) inhibitors in clinical cardiovascular diseases. Atrial electrical and structural remodeling is important as an atrial fibrillation (AF) substrate. Methods and Results The present study assessed the effect of canagliflozin (CAN), an SGLT2 inhibitor, on atrial remodeling in a canine AF model. The study included 12 beagle dogs, with 10 receiving continuous rapid atrial pacing and 2 acting as the nonpacing group. The 10 dogs that received continuous rapid atrial pacing for 3 weeks were subdivided as follows: pacing control group (n=5) and pacing+CAN (3 mg/kg per day) group (n=5). The atrial effective refractory period, conduction velocity, and AF inducibility were evaluated weekly through atrial epicardial wires. After the protocol, atrial tissues were sampled for histological examination. The degree of reactive oxygen species expression was evaluated by dihydroethidium staining. The atrial effective refractory period reduction was smaller (P=0.06) and the degree of conduction velocity decrease was smaller in the pacing+CAN group compared with the pacing control group (P=0.009). The AF inducibility gradually increased in the pacing control group, but such an increase was suppressed in the pacing+CAN group (P=0.011). The pacing control group exhibited interstitial fibrosis and enhanced oxidative stress, which were suppressed in the pacing+CAN group. Conclusions CAN and possibly other SGLT2 inhibitors might be useful for preventing AF and suppressing the promotion of atrial remodeling as an AF substrate.
Background Recent clinical trials have demonstrated the possible pleiotropic effects of SGLT2 (sodium-glucose cotransporter 2) inhibitors in clinical cardiovascular diseases. Atrial electrical and structural remodeling is important as an atrial fibrillation (AF) substrate. Methods and Results The present study assessed the effect of canagliflozin (CAN), an SGLT2 inhibitor, on atrial remodeling in a canine AF model. The study included 12 beagle dogs, with 10 receiving continuous rapid atrial pacing and 2 acting as the nonpacing group. The 10 dogs that received continuous rapid atrial pacing for 3 weeks were subdivided as follows: pacing control group (n=5) and pacing+CAN (3 mg/kg per day) group (n=5). The atrial effective refractory period, conduction velocity, and AF inducibility were evaluated weekly through atrial epicardial wires. After the protocol, atrial tissues were sampled for histological examination. The degree of reactive oxygen species expression was evaluated by dihydroethidium staining. The atrial effective refractory period reduction was smaller ( =0.06) and the degree of conduction velocity decrease was smaller in the pacing+CAN group compared with the pacing control group ( =0.009). The AF inducibility gradually increased in the pacing control group, but such an increase was suppressed in the pacing+CAN group ( =0.011). The pacing control group exhibited interstitial fibrosis and enhanced oxidative stress, which were suppressed in the pacing+CAN group. Conclusions CAN and possibly other SGLT2 inhibitors might be useful for preventing AF and suppressing the promotion of atrial remodeling as an AF substrate.
Author Sakagami, Hiroyuki
Kishihara, Jun
Fukaya, Hidehira
Niwano, Hiroe
Hara, Yoshinobu
Ishizue, Naruya
Ako, Junya
Yoshizawa, Tomoharu
Nakamura, Hironori
Arakawa, Yuki
Nishinarita, Ryo
Sato, Tetsuro
Katsumura, Takafumi
Horiguchi, Ai
Kobayashi, Shuhei
Oikawa, Jun
Matsuura, Gen
Shirakawa, Yuki
Igarashi, Tazuru
Satoh, Akira
Saito, Daiki
Niwano, Shinichi
AuthorAffiliation 5 Department of Cardiovascular Medicine Yokohama Asahi Central Hospital Yokohama Japan
3 Department of Cardiovascular Medicine Nerima Hikarigaoka Hospital Nerima Japan
4 Department of Cardiovascular Medicine Yamato Municipal Hospital Yamato Japan
6 Department of Anatomy Kitasato University School of Medicine Sagamihara Japan
1 Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan
2 Department of Education Tamagawa University, College of Education Machida Japan
AuthorAffiliation_xml – name: 2 Department of Education Tamagawa University, College of Education Machida Japan
– name: 6 Department of Anatomy Kitasato University School of Medicine Sagamihara Japan
– name: 1 Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan
– name: 5 Department of Cardiovascular Medicine Yokohama Asahi Central Hospital Yokohama Japan
– name: 3 Department of Cardiovascular Medicine Nerima Hikarigaoka Hospital Nerima Japan
– name: 4 Department of Cardiovascular Medicine Yamato Municipal Hospital Yamato Japan
Author_xml – sequence: 1
  givenname: Ryo
  orcidid: 0000-0003-0329-5476
  surname: Nishinarita
  fullname: Nishinarita, Ryo
  organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan
– sequence: 2
  givenname: Shinichi
  surname: Niwano
  fullname: Niwano, Shinichi
  organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan
– sequence: 3
  givenname: Hiroe
  surname: Niwano
  fullname: Niwano, Hiroe
  organization: Department of Education Tamagawa University, College of Education Machida Japan
– sequence: 4
  givenname: Hironori
  surname: Nakamura
  fullname: Nakamura, Hironori
  organization: Department of Cardiovascular Medicine Nerima Hikarigaoka Hospital Nerima Japan
– sequence: 5
  givenname: Daiki
  surname: Saito
  fullname: Saito, Daiki
  organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan
– sequence: 6
  givenname: Tetsuro
  surname: Sato
  fullname: Sato, Tetsuro
  organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan
– sequence: 7
  givenname: Gen
  orcidid: 0000-0003-0165-5677
  surname: Matsuura
  fullname: Matsuura, Gen
  organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan
– sequence: 8
  givenname: Yuki
  surname: Arakawa
  fullname: Arakawa, Yuki
  organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan
– sequence: 9
  givenname: Shuhei
  surname: Kobayashi
  fullname: Kobayashi, Shuhei
  organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan
– sequence: 10
  givenname: Yuki
  surname: Shirakawa
  fullname: Shirakawa, Yuki
  organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan
– sequence: 11
  givenname: Ai
  surname: Horiguchi
  fullname: Horiguchi, Ai
  organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan
– sequence: 12
  givenname: Naruya
  surname: Ishizue
  fullname: Ishizue, Naruya
  organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan
– sequence: 13
  givenname: Tazuru
  surname: Igarashi
  fullname: Igarashi, Tazuru
  organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan
– sequence: 14
  givenname: Tomoharu
  surname: Yoshizawa
  fullname: Yoshizawa, Tomoharu
  organization: Department of Cardiovascular Medicine Yamato Municipal Hospital Yamato Japan
– sequence: 15
  givenname: Jun
  surname: Oikawa
  fullname: Oikawa, Jun
  organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan
– sequence: 16
  givenname: Yoshinobu
  orcidid: 0000-0001-6339-5116
  surname: Hara
  fullname: Hara, Yoshinobu
  organization: Department of Anatomy Kitasato University School of Medicine Sagamihara Japan
– sequence: 17
  givenname: Takafumi
  surname: Katsumura
  fullname: Katsumura, Takafumi
  organization: Department of Anatomy Kitasato University School of Medicine Sagamihara Japan
– sequence: 18
  givenname: Jun
  surname: Kishihara
  fullname: Kishihara, Jun
  organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan
– sequence: 19
  givenname: Akira
  surname: Satoh
  fullname: Satoh, Akira
  organization: Department of Cardiovascular Medicine Yokohama Asahi Central Hospital Yokohama Japan
– sequence: 20
  givenname: Hidehira
  surname: Fukaya
  fullname: Fukaya, Hidehira
  organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan
– sequence: 21
  givenname: Hiroyuki
  surname: Sakagami
  fullname: Sakagami, Hiroyuki
  organization: Department of Anatomy Kitasato University School of Medicine Sagamihara Japan
– sequence: 22
  givenname: Junya
  surname: Ako
  fullname: Ako, Junya
  organization: Department of Cardiovascular Medicine Kitasato University School of Medicine Sagamihara Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33399004$$D View this record in MEDLINE/PubMed
BookMark eNp1kc1rVDEUxYNUbDt27U7e0s20eS_fG2EYrG2pKH6sQ15yM6ZkkjF5I-hfb6bTkVYwBHLJPed34Z5TdJRyAoRe9fi873l_cbO4WrRKneNeUEmeoZMBUzFXSuKjR_UxOqv1DrfDB0GYeoGOCSFKYUxP0KelSWYVg4_5d0jdl-1mU6BWqN1iKsHE7jOss4MY0qprfdM1fUhw6F6GsYQYzRRy6j7shC_Rc29ihbOHd4a-Xb77urya3358f71c3M4tG9g0lw47S5jwfhwl9Yr0wozAueHWD5yIJhJgqZDSGTc4odwgKLeOM--pxUBm6HrPddnc6U0Ja1N-6WyCvv_IZaVNmYKNoI1jIKkaxx5TKrmUHBPfUIOwhBowjfV2z9psxzU4C2kqJj6BPu2k8F2v8k8tFGNk6BvgzQOg5B9bqJNeh2qhLSZB3lY9UMGIors7Q68fz_o75BBJE7C9wJZcawGvbZjuF9xGh6h7rHfp6136rVJ6n37zXfzjO6D_5_gDc4axcQ
CitedBy_id crossref_primary_10_1097_FJC_0000000000001183
crossref_primary_10_1016_j_biopha_2024_117453
crossref_primary_10_1016_j_intimp_2023_111038
crossref_primary_10_3389_fcvm_2022_902923
crossref_primary_10_1016_j_ijcard_2024_132954
crossref_primary_10_2174_1570161120666211227125033
crossref_primary_10_3390_cells12131796
crossref_primary_10_3390_cimb46090571
crossref_primary_10_4239_wjd_v14_i5_512
crossref_primary_10_1007_s00210_024_03225_1
crossref_primary_10_1152_physiol_00008_2024
crossref_primary_10_1016_j_amjmed_2023_04_035
crossref_primary_10_3390_antiox14030336
crossref_primary_10_1016_j_tcm_2022_04_003
crossref_primary_10_1186_s12933_023_01913_5
crossref_primary_10_1002_jcu_23384
crossref_primary_10_1007_s11010_024_05084_z
crossref_primary_10_1111_dom_14854
crossref_primary_10_3390_cells11182915
crossref_primary_10_1016_j_heliyon_2023_e16835
crossref_primary_10_2337_dc22_0714
crossref_primary_10_1111_pace_15038
crossref_primary_10_1111_jce_16554
crossref_primary_10_2459_JCM_0000000000001523
crossref_primary_10_3389_fcvm_2022_903902
crossref_primary_10_3390_jcm13185408
crossref_primary_10_1080_10520295_2023_2262390
crossref_primary_10_3390_ijms23031416
crossref_primary_10_1016_j_jstrokecerebrovasdis_2021_106159
crossref_primary_10_1093_cvr_cvae101
crossref_primary_10_3390_diagnostics11030449
crossref_primary_10_3390_ijms25147711
crossref_primary_10_3390_biomedicines11072085
crossref_primary_10_1007_s40265_021_01565_3
crossref_primary_10_3390_ijms25010535
crossref_primary_10_1016_j_cbi_2024_111229
crossref_primary_10_3390_physiologia3010004
crossref_primary_10_1002_ehf2_13930
crossref_primary_10_3390_antiox13111396
crossref_primary_10_3390_ijms22115937
crossref_primary_10_3390_life13020443
crossref_primary_10_1016_j_jpha_2023_12_007
crossref_primary_10_3389_fcvm_2023_1005408
Cites_doi 10.1161/CIRCULATIONAHA.111.029223
10.2337/dc16-0542
10.1056/NEJMoa1911303
10.1152/ajpheart.00646.2012
10.2337/dc16-0330
10.18637/jss.v082.i13
10.1007/s00380-018-1170-0
10.1093/europace/eus052
10.1530/JOE-17-0457
10.1056/NEJMoa1504720
10.1161/CIRCULATIONAHA.115.017355
10.1056/NEJMoa1812389
10.1136/heartjnl-2012-301952
10.1126/science.1227166
10.1161/01.CIR.104.2.174
10.1016/j.ijcard.2006.04.026
10.1161/CIRCULATIONAHA.115.017545
10.1253/circj.72.318
10.1056/NEJMoa1611925
10.1046/j.1540-8167.2001.00183.x
10.1016/j.bbadis.2015.01.010
10.1016/j.freeradbiomed.2003.07.002
10.1093/cvr/cvx151
10.1007/s00380-016-0874-2
10.1089/ars.2013.5542
10.1111/jdi.13009
10.1161/01.CIR.92.7.1954
ContentType Journal Article
Copyright 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
Copyright_xml – notice: 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.1161/JAHA.119.017483
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Canagliflozin Suppresses Atrial Remodeling of AF
EISSN 2047-9980
ExternalDocumentID oai_doaj_org_article_ad5e849bb10448688603fcd627c34aea
PMC7955321
33399004
10_1161_JAHA_119_017483
Genre Journal Article
GroupedDBID 0R~
1OC
24P
53G
5VS
8-1
AAYXX
AAZKR
ACCMX
ACGFO
ACXQS
ADBBV
ADKYN
ADZMN
AEGXH
AENEX
AIAGR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AVUZU
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GODZA
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
RAH
RNS
RPM
NPM
7X8
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
5PM
WIN
ID FETCH-LOGICAL-c525t-8d0dc357ffbb84f9317abe66a6cf26375257ec4788dad2d79d2746cd65ff4c0e3
IEDL.DBID M48
ISSN 2047-9980
IngestDate Wed Aug 27 01:31:41 EDT 2025
Thu Aug 21 18:17:22 EDT 2025
Fri Jul 11 01:14:54 EDT 2025
Thu Apr 03 06:56:18 EDT 2025
Thu Apr 24 22:53:18 EDT 2025
Tue Jul 01 04:01:56 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords atrial remodeling
sodium–glucose cotransporter 2 inhibitor
atrial fibrillation
oxidative stress
canagliflozin
Language English
License This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c525t-8d0dc357ffbb84f9317abe66a6cf26375257ec4788dad2d79d2746cd65ff4c0e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
For Sources of Funding and Disclosures, see page 11.
ORCID 0000-0003-0165-5677
0000-0001-6339-5116
0000-0003-0329-5476
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1161/JAHA.119.017483
PMID 33399004
PQID 2475394394
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_ad5e849bb10448688603fcd627c34aea
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7955321
proquest_miscellaneous_2475394394
pubmed_primary_33399004
crossref_citationtrail_10_1161_JAHA_119_017483
crossref_primary_10_1161_JAHA_119_017483
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-01-19
PublicationDateYYYYMMDD 2021-01-19
PublicationDate_xml – month: 01
  year: 2021
  text: 2021-01-19
  day: 19
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Hoboken
PublicationTitle Journal of the American Heart Association
PublicationTitleAlternate J Am Heart Assoc
PublicationYear 2021
Publisher John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley and Sons Inc
– name: Wiley
References e_1_3_1_22_2
e_1_3_1_23_2
e_1_3_1_24_2
e_1_3_1_8_2
e_1_3_1_7_2
e_1_3_1_9_2
e_1_3_1_20_2
e_1_3_1_4_2
e_1_3_1_29_2
e_1_3_1_3_2
e_1_3_1_6_2
e_1_3_1_25_2
e_1_3_1_26_2
e_1_3_1_2_2
e_1_3_1_27_2
e_1_3_1_28_2
Kishihara J (e_1_3_1_5_2) 2014; 4
Xie W (e_1_3_1_21_2) 2015; 5
e_1_3_1_13_2
e_1_3_1_12_2
e_1_3_1_11_2
e_1_3_1_30_2
e_1_3_1_10_2
e_1_3_1_17_2
e_1_3_1_16_2
e_1_3_1_15_2
e_1_3_1_14_2
e_1_3_1_19_2
e_1_3_1_18_2
References_xml – ident: e_1_3_1_20_2
  doi: 10.1161/CIRCULATIONAHA.111.029223
– ident: e_1_3_1_23_2
  doi: 10.2337/dc16-0542
– ident: e_1_3_1_11_2
  doi: 10.1056/NEJMoa1911303
– ident: e_1_3_1_25_2
  doi: 10.1152/ajpheart.00646.2012
– ident: e_1_3_1_22_2
  doi: 10.2337/dc16-0330
– volume: 5
  start-page: 1
  year: 2015
  ident: e_1_3_1_21_2
  article-title: Mitochondrial oxidative stress promotes atrial fibrillation
  publication-title: Sci Rep
– ident: e_1_3_1_15_2
  doi: 10.18637/jss.v082.i13
– ident: e_1_3_1_7_2
  doi: 10.1007/s00380-018-1170-0
– ident: e_1_3_1_6_2
  doi: 10.1093/europace/eus052
– ident: e_1_3_1_30_2
  doi: 10.1530/JOE-17-0457
– ident: e_1_3_1_10_2
  doi: 10.1056/NEJMoa1504720
– ident: e_1_3_1_29_2
  doi: 10.1161/CIRCULATIONAHA.115.017355
– ident: e_1_3_1_9_2
  doi: 10.1056/NEJMoa1812389
– ident: e_1_3_1_17_2
  doi: 10.1136/heartjnl-2012-301952
– ident: e_1_3_1_24_2
  doi: 10.1126/science.1227166
– ident: e_1_3_1_2_2
  doi: 10.1161/01.CIR.104.2.174
– ident: e_1_3_1_3_2
  doi: 10.1016/j.ijcard.2006.04.026
– ident: e_1_3_1_28_2
  doi: 10.1161/CIRCULATIONAHA.115.017545
– ident: e_1_3_1_13_2
  doi: 10.1253/circj.72.318
– ident: e_1_3_1_8_2
  doi: 10.1056/NEJMoa1611925
– ident: e_1_3_1_18_2
  doi: 10.1046/j.1540-8167.2001.00183.x
– ident: e_1_3_1_26_2
  doi: 10.1016/j.bbadis.2015.01.010
– ident: e_1_3_1_16_2
  doi: 10.1016/j.freeradbiomed.2003.07.002
– ident: e_1_3_1_14_2
  doi: 10.1093/cvr/cvx151
– volume: 4
  start-page: 28
  year: 2014
  ident: e_1_3_1_5_2
  article-title: Effect of carvedilol on atrial remodeling in canine model of atrial fibrillation
  publication-title: Cardiovasc Diagn Ther
– ident: e_1_3_1_12_2
  doi: 10.1007/s00380-016-0874-2
– ident: e_1_3_1_4_2
  doi: 10.1089/ars.2013.5542
– ident: e_1_3_1_27_2
  doi: 10.1111/jdi.13009
– ident: e_1_3_1_19_2
  doi: 10.1161/01.CIR.92.7.1954
SSID ssj0000627359
Score 2.4347646
Snippet Background Recent clinical trials have demonstrated the possible pleiotropic effects of SGLT2 (sodium-glucose cotransporter 2) inhibitors in clinical...
Background Recent clinical trials have demonstrated the possible pleiotropic effects of SGLT2 (sodium–glucose cotransporter 2) inhibitors in clinical...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e017483
SubjectTerms atrial fibrillation
atrial remodeling
canagliflozin
Original Research
oxidative stress
sodium–glucose cotransporter 2 inhibitor
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA7iQbyIb-uLCh68VLt5NsdVXBZhRcQFbyVtJrpQuuKuF3-9k7S77IrixVtoEhpmJplvyOQbQs6LVBoOvJMg-qYJFwwSQyFLnKUmnH-W-bfDg3vZH_K7Z_G8UOrL54Q19MCN4K6MFZBxXRQYN_BMZplMmSutpKpk3ECARujzFoKp5gxGtyx0y-WDqObqrtvvYktfognyjC25ocDW_xPE_J4pueB6eptko8WMcbdZ6xZZgXqbrA3aW_Ed8uApBl6qkavGn6M69oU6AyX4JO6GohzxI4SCN-ilYuw3MY7HibPens_6r5qcuNjXRqt2ybB3-3TTT9pKCUkpqJgmmU1tyYRyrigy7jSCAlOAlEaWjkqmPOUplJ4p3xpLrdIWg1GJUhTO8TIFtkdW63ENBySm1F_NGQsKkRJNnZHWGQWgHAKPTgoRuZwJLi9bGnFfzaLKQzghO7mXNLZ03kg6IhfzCW8Ng8bvQ6-9JubDPPV1-IAGkbcGkf9lEBE5m-kxx63i7z9MDeOPSU45xmbaPwWOyH6j1_mvGEOkhgdGRNSSxpfWstxTj14DHbfSQjDaOfyPxR-RdeqTZlLcPPqYrE7fP-AEUc-0OA0G_gWcf_9Q
  priority: 102
  providerName: Directory of Open Access Journals
Title Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model
URI https://www.ncbi.nlm.nih.gov/pubmed/33399004
https://www.proquest.com/docview/2475394394
https://pubmed.ncbi.nlm.nih.gov/PMC7955321
https://doaj.org/article/ad5e849bb10448688603fcd627c34aea
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-2Dkpfxr7ntise7GEvzmx9Wg-jZGMhFDLGWKBvRrakNmCcLUmh21_fkyxny8he9mYsHbZ1d7o7S_r9AN7UudDMsiLD7JtkjFObaWLLzBmiw_xnqD87PPsspnN2cckvf9MBxQFc7y3tPJ_UfNWObn_8PEeHfx8cXhTvLsbTMV6pEVoXK-l9eIBhSXovncVcv5-WMVJzFeF99sgdwSGlGK_zSNo2BKmA5b8vAf17H-UfgWnyCB7GjDId9ybwGO7Z7gkczuKa-VP44gEIrtqFa5e_Fl3qaTwDYPg6HQfKjvSrDXQ4GMNSbNcp9kfBoXXizwS0_Y651DOntc9gPvn07eM0izwKWcMJ32SlyU1DuXSurkvmFKYMurZCaNE4Iqj0gKi28Tj6RhtipDJYqorGCO4ca3JLn8NBt-zsS0gJ8Qt32liJeRTJnRbGaWmtdJiWFLlNYDQMXNVEkHHPddFWodgQReUHHa9U1Q96Am-3At97fI1_d_3gNbHt5oGxw43l6qqKflZpw23JVF1jmclKUZYipw4_hciGMm11Aq8HPVboSH51RHd2ebOuCMPKTfmDwgm86PW6fdRgFwnIHY3vvMtuS7e4DmDdUnFOSXH835IncET8Ppoc_UmdwsFmdWNfYSK0qc_CD4SzYOZ3WQsHog
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Canagliflozin+Suppresses+Atrial+Remodeling+in+a+Canine+Atrial+Fibrillation+Model&rft.jtitle=Journal+of+the+American+Heart+Association&rft.au=Nishinarita%2C+Ryo&rft.au=Niwano%2C+Shinichi&rft.au=Niwano%2C+Hiroe&rft.au=Nakamura%2C+Hironori&rft.date=2021-01-19&rft.pub=John+Wiley+and+Sons+Inc&rft.eissn=2047-9980&rft.volume=10&rft.issue=2&rft_id=info:doi/10.1161%2FJAHA.119.017483&rft_id=info%3Apmid%2F33399004&rft.externalDocID=PMC7955321
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-9980&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-9980&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-9980&client=summon